This company listing is no longer active
Eden Empire Past Earnings Performance
Past criteria checks 0/6
Key information
-24.3%
Earnings growth rate
19.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 119.0% |
| Return on equity | n/a |
| Net Margin | -1,716.9% |
| Last Earnings Update | 30 Apr 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Eden Empire makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 22 | 0 | -5 | 2 | 0 |
| 31 Jan 22 | 0 | -5 | 2 | 0 |
| 31 Oct 21 | 0 | -4 | 2 | 0 |
| 31 Jul 21 | 0 | -4 | 2 | 0 |
| 30 Apr 21 | 0 | -5 | 3 | 0 |
| 31 Jan 21 | 0 | -4 | 2 | 0 |
| 31 Oct 20 | 0 | -4 | 2 | 0 |
| 31 Jul 20 | 0 | -5 | 3 | 0 |
| 30 Apr 20 | 0 | -3 | 3 | 0 |
Quality Earnings: EDEN is currently unprofitable.
Growing Profit Margin: EDEN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EDEN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EDEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
Return on Equity
High ROE: EDEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.